WO2002003684A2 - Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist - Google Patents

Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist Download PDF

Info

Publication number
WO2002003684A2
WO2002003684A2 PCT/US2001/014863 US0114863W WO0203684A2 WO 2002003684 A2 WO2002003684 A2 WO 2002003684A2 US 0114863 W US0114863 W US 0114863W WO 0203684 A2 WO0203684 A2 WO 0203684A2
Authority
WO
WIPO (PCT)
Prior art keywords
thiadiazol
tetrahydro
methylpyridine
component
antipsychotic
Prior art date
Application number
PCT/US2001/014863
Other languages
French (fr)
Other versions
WO2002003684A3 (en
Inventor
Franklin Porter Bymaster
Harlan Edgar Shannon
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Priority to JP2002507636A priority Critical patent/JP2004502655A/en
Priority to US10/296,738 priority patent/US20040023951A1/en
Priority to AU2001268055A priority patent/AU2001268055A1/en
Priority to EP01945949A priority patent/EP1316203A2/en
Priority to CA002411386A priority patent/CA2411386A1/en
Publication of WO2002003684A2 publication Critical patent/WO2002003684A2/en
Publication of WO2002003684A3 publication Critical patent/WO2002003684A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • the present invention belongs to the fields of pharmacology, medicine, and medicinal chemistry, and provides methods and compositions for the treatment of a disorders, including psychoses.
  • Psychoses are serious mental illnesses characterized by defective reality or lost contact with reality. Psychotic patients may suffer hallucinations, delusions, and grossly disorganized behavior as part of their disease. Psychoses exact a tremendous emotional and economic toll on the patients, their families, and society as a whole. For example, it has been estimated that as many as 50% of the homeless people living in the United States are psychotic. (Bachrach, Treating the Homeless Mentally 111, Washington, D.C., American Psychiatric Press, 1340, Lamb et al . ed. (1992)). In addition, approximately 2.5% of the total dollars spent for health care in the United States is spent in the treatment of psychoses (Rupp et al . , Psychiatric Clin. North Am. , 16:413-423 (1993)).
  • the present invention addresses these needs by providing a method of treating psychosis, and other disorders as described herein, by the synergistic effect of combination therapy of a typical or atypical antipsychotic and a muscarinic agonist.
  • the invention provides a method for treating a patient suffering from or susceptible to psychosis, comprising administering to the patient an effective amount a first component which is a typical antipsychotic or an atypical antipsychotic and an effective amount of a second component which is a muscarinic agonist.
  • the invention also provides a pharmaceutical composition which comprises a first component which is a typical antipsychotic or an atypical antipsychotic, and a second component which is a muscarinic agonist.
  • the present invention provides the use of a pharmaceutical composition
  • a pharmaceutical composition comprising an effective amount of a first component which is a typical antipsychotic or an atypical antipsychotic, in combination with an effective amount of a second component which is a muscarinic agonist for treating psychosis.
  • the present invention provides for treatment for patients suffering from psychosis comprising the administration of a typical antipsychotic or an atypical antipsychotic and a muscarinic agonist. It has been discovered that the administration of a typical antipsychotic or an atypical antipsychotic and a muscarinic agonist unexpectedly enhances the therapeutic effect of the combination. That is, the combined administration of a typical antipsychotic or an atypical antipsychotic and a muscarinic agonist provides a synergistic effect. Thus, the combination therapy of the present invention provides an effective treatment of psychoses with lessened side effects and of broader applicability than each of the individual components alone.
  • the term "psychosis” includes schizophrenia, schizophreniform diseases, mania, schizoaffective disorders, and depression with psychotic features.
  • the above mentioned conditions represent multiple disease states.
  • schizophrenia is referred to in various forms as catatonic, disorganized, paranoid, undifferential, residual, among others. All the various forms of the disorders mentioned herein are contemplated as part of the present invention.
  • DSM IV Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, published by the American Psychiatric Association (DSM IV) : Paranoid Type Schizophrenia, Disorganized Type Schizophrenia, Catatonic Type Schizophrenia, Undifferentiated Type Schizophrenia, Residual Type Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder, Psychotic Disorder Due to a General Medical Condition, Substance-Induced Psychotic Disorder, Psychotic Disorder Not Otherwise Specified, Major Depressive Disorder with Psychotic Features, Bipolar Disorder I, Bipolar Disorder II, Bipolar Disorder Not Otherwise Specified, Schizoid Personality Disorder, and
  • disorders that are treated by the present combination include, dementia, including Alzheimer's disease, mood disorders, including depression, anxiety disorders, including general anxiety disorder and panic disorder, adjustment disorders, decreased cognition.
  • patient refers to a mammal and includes, mice, rats, dogs, sheep, cattle, pigs, guinea pigs, cats, chimpanzees, monkeys, apes, and humans, etc.
  • patient refers to a mammal and includes, mice, rats, dogs, sheep, cattle, pigs, guinea pigs, cats, chimpanzees, monkeys, apes, and humans, etc.
  • the term includes a human suffering from psychosis.
  • an effective amount of a first component and "an effective amount a second component” refers to the amounts of typical antipsychotic or an atypical antipsychotic and amounts of a muscarinic agonist, respectively, which, upon single or multiple administration to the patient, is synergistically effective in alleviating or controlling the disorders described herein, and in particular psychosis.
  • An effective amount of a first component and an effective amount of a second component can be readily determined by the attending diagnostician, as one skilled in the art, by the use of conventional techniques and by observing results..
  • a number of factors are considered by the attending diagnostician, including, but not limited to: the properties of the individual components, the properties of the components in combination as determined in preclinical and clinical trials, the dose of each component, the species of mammal; its size, age, and general health; the specific disorder (s) involved; the degree of involvement or the severity of the disorder (s) ; the response of the individual patient; the mode of administration; the bioavailability of the formulation administered; the dose regimen selected; and other factors known in the art .
  • xanomeline from about 1 to 225 mg per day, preferred; and most preferably about 25 to 125 mg per day; and for olanzapine from about 0.25 to 50 mg, once/day; preferred, from 1 to 30 mg, once/day; and most preferably 1 to 25 mg once/day.
  • the class of compounds referred to a "typical antipsychotic" are effective in improving symptoms of psychoses, and in particular schizophrenia, by acting as dopamine receptor antagonists, more particularly D dopamine receptor antagonists, which also are known as D 2 dopamine receptor blockading agents.
  • D dopamine receptor antagonists which also are known as D 2 dopamine receptor blockading agents.
  • typical antipsychotic include those drugs known as typical neuroleptics .
  • typically antipsychotic includes, but is not limited to, thiopropazate, chlorpromazine, triflupromazine, esoridazine, piperacetazine, thioridazine, acetophenazine, fluphenazine, perphenazine, trifluoperazine, chlorprathixene, thiothixene, haloperidol , bromperidol, loxapine, molindone, loxapine, molindone, and pimozide. These compound are well known in the art .
  • the class of compounds referred to a "atypical antipsychotic” are effective in improving symptoms of psychoses, and in particular schizophrenia. These compounds act be a variety of mechanisms, including antagonism of D 2 , D 3 and D 4 dopamine neurons, 5-HT 2 receptors, and an alpha 2 - adrenergic receptors.
  • the term "atypical antipsychotic” include those drugs known as atypical neuroleptics .
  • the term "atypical antipsychotic” includes, but is not limited to, clozapine, 8-chloro-ll- (4- methyl-1-piperazinyl) -5H-dibenzo [b, e] [1, 4] diazepine (U.S. Patent No.
  • muscle agonists are effective in improving symptoms of psychoses, and in particular schizophrenia.
  • the term “muscarinic agonist” includes, but is not limited to, pilocarpine, oxotre orine, bethanechol , carachol , sabcomeline, milameline, talsaclidine, and the compounds of the formula I, II, and III below:
  • W is oxygen or sulfur
  • R is selected from the group consisting of -OR 4 , -SR 4 ,
  • R 4 is selected from the group consisting of C - s-alkyl,
  • C 2 -1 5 _ alkenyl and C 2 -i5-alkynyl each of which is optionally substituted with one or more independently selected from the group consisting of halogen(s), -CF 3 , -CN, C - 4 -alkoxy, phenyl, and phenoxy wherein the phenyl or phenoxy is optionally substituted with one or more independently selected from the group consisting of halogen, -CN, C ⁇ _ 4 -alkyl, C - ⁇ -alkoxy, -OCF 3 , -CF 3 , -CONH 2 and -CSNH 2 ;
  • Z is oxygen or sulphur;
  • Z 2 is oxygen or sulphur
  • G is selected from the group consisting of:
  • R 1 and R 2 independently are selected from the group consisting of hydrogen, C ⁇ _i 5 -alkyl, C 2 - 5 -alkenyl, C 2 - 5 - alkynyl, C _ ⁇ o-alkoxy, and C ⁇ _ 5 -alkyl substituted with one or more independently selected from the group consisting of -OH, -COR 6 , CH 2 -OH, halogen, -NH 2 , carboxy, and phenyl;
  • R 6 is hydrogen, Ci-g-alkyl
  • R 3 is selected from the group consisting of hydrogen
  • R5 is selected from the group consisting of -OR 4 , -SR 4 , R 4 is selected from the group consisting of C ⁇ _ 15 -alkyl, C 2 -i 5 ⁇ alkenyl and C 2 -i 5 -alkynyl, each of which is optionally substituted with one or more independently selected from the group consisting of halogen (s), -CF 3 , -CN, C ⁇ - 4 -alkoxy, phenyl, and phenoxy wherein the phenyl or phenoxy is optionally substituted with one or more independently selected from the group consisting of halogen, -CN, Ci- 4 -alkyl, C ⁇ _ 4 -alkoxy, -OCF 3 , -CF 3 , -CONH 2 and -CSNH 2 ; Zx is oxygen or sulphur,
  • R7 is selected from the group consisting of hydrogen, c ⁇ -i 5 ⁇ alkyl, C 2 - 5 ⁇ alkenyl, C 2 - 5 ⁇ alkynyl ;
  • R8 is selected from the group consisting of hydrogen, and C ⁇ - 4 -alkyl; or a pharmaceutically acceptable salt thereof;
  • W is oxygen or sulfur
  • R is selected from the group consisting of -OR 4 , -SR 4 , -Z-C 3 _ ⁇ o-cycloalkyl and -Z-C 4 _i 2 ⁇ (cycloalkylalkyl) ;
  • R 4 is selected from the group consisting of C ⁇ _ 5 -alkyl, c 2 - 15 _ alkenyl and C 2 -i 5 -alkynyl , each of which is optionally substituted with one or more independently selected from the group consisting of haloge (s), -CF 3 , -CN, C ⁇ - 4 -alkoxy, phenyl, and phenoxy wherein the phenyl or phenoxy is optionally substituted with one or more independently selected from the group consisting of halogen, -CN, C ⁇ - 4 -alkyl, C ⁇ _ 4 -alkoxy, -OCF 3 , -CF 3 , -CONH 2 and -CSNH 2 ; Z is oxygen or sulphur,
  • G is selected from the group consisting of:
  • R 1 and R 2 independently are selected from the group consisting of hydrogen, C ⁇ - 15 -alkyl , C2- 5 ⁇ alkenyl , C 2 - 5 - alkynyl, C ⁇ - 10 -alkoxy, and C ⁇ - 5 -alkyl substituted with one or more independently selected from the group consisting of -OH, -COR 6 , CH 2 -OH, halogen, -NH2, carboxy, and phenyl; R 6 is hydrogen, C ⁇ - 6 -alkyl;
  • R 3 is selected from the group consisting of hydrogen, C ⁇ - 5 -alkyl, C 2 - 5 -alkenyl and C 2 - 5 ⁇ alkynyl ; n is 1 or 2 m is 1 or 2 ; p is 1 or 2 q is 1 or 2 r is 0, 1 or 2; or a pharmaceutically acceptable salt thereof.
  • Preferred compounds of formula I are (+) 3- ⁇ 3- [4- (trifluoromethyl) phenyl] propylthio ⁇ -4- [-3- (1- azabicyclo [2.2.2] octyloxy) ] -1,2, 5-thiadiazole, ( ⁇ ) -3- Methoxy-4- (1-azabicyclo [2.2.2] octyl-3-oxy) -1,2,5- thiadiazole, ( ⁇ ) -3-Ethoxy-4- (1-azabicyclo [2.2.2] octyl-3- oxy) -1,2, 5-thiadiazole, (+) -3-Propyloxy-4- (1- azabicyclo [2.2.2] octyl-3-oxy) -1, 2, 5-thiadiazole, (+) -3-Propyloxy-4- (1- azabicyclo [2.2.2] octyl-3-oxy) -1, 2, 5-thiadiazole, (+) -3-Propyloxy-4-
  • a more particularly preferred compound of formula II is xanomeline, 3- (4-hexyloxy-l, 2 , 5-thiadiazol-3-yl) -1, 2 , 5, 6- tetrahydro-1-methylpyridine .
  • Preferred compounds of formula III are 2- [exo- (+/-) -3- [1-azabicyclo [3.2.1] octyloxy) ]pyrazine, 3-butylthio-2- (1- azabicyclo [2.2.2] ocytl-3-oxy) ] pyrazine, 3-butyloxy-2- [3-+- endo- (1-azabicyclo [2.2.1] heptyloxy) ] pyrazine, 3-(2- butynyloxy) -2- [6- ⁇ -endo- (1- azabicyclo [3.2.1] octyloxy) pyrazine, 3-hexylthio-2- [6- ⁇ -exo- (2 -azabicyclo [2.2.1] heptyloxy) ] yrazine, 3- (3- phenylpropynylthio) -2- [2- ⁇ -exo- (7-azabicyclo [2.2.1] heptyloxy) ]
  • the first component is either a typical or an atypical antipsychotic.
  • the second component compound is a compound which functions as a muscarinic agonist . It will be understood that while the use of a single typical antipsychotic or a single atypical antipsychotic as a first component compound is preferred, combinations of two or more antipsychotic may be used as a first component if necessary or desired. Similarly, while the use of a single muscarinic agonist as a second component compound is preferred, combinations of two or more muscarinic agonists may be used as a second component if necessary or desired.
  • first and second component compounds are useful and valuable, certain combinations are particularly valued and are preferred.
  • combinations and methods of treatment using an atypical antipsychotic as the first component are preferred.
  • Particularly preferred combinations and methods of treatment using olanzapine as the first component are preferred.
  • combinations and methods of treatment using xanomeline as the second component are preferred.
  • Especially preferred are combinations and methods use olanzapine as the first component and xanomeline as the second component. It is especially preferred that when the first component is olanzapine, it will be the Form II olanzapine polymorph as described in U.S. Patent No. 5,229,382.
  • Form II olanzapine is characterized by x-ray powder diffraction pattern, of a well prepared sample, having an interplanar spacing at 10.2689.
  • substantially pure refers to Form II associated with less than about 5% Form I, preferably less than about 2% Form I, and more preferably less than about 1% Form I. Further,
  • substantially pure Form II will contain less than about 0.5% related substances, wherein “related substances” refers to undesired chemical impurities or residual solvent or water.
  • substantially pure Form II should contain less than about 0.05% content of acetonitrile, more preferably, less than about 0.005% content of acetonitrile.
  • the polymorph of the invention should contain less than 0.5% of associated water.
  • olanzapine embraces all solvate and polymorphic forms except where specifically indicated.
  • halogen means a fluoro, chloro, bromo, or iodo atom.
  • Cx-xs-alkyl represents a branched or linear alkyl group having from one to fifteen carbon atoms.
  • Typical C ⁇ - ⁇ 5 alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, butyl, iso-butyl, sec- butyl, tert-butyl, pentyl, hexyl , heptyl, octyl, nonyl, decyl, and the like.
  • C ⁇ - 4 -alkyl represents a branched or linear alkyl group having from one to four carbon atoms .
  • Typical C1-C4 alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, butyl, iso-butyl, sec-butyl, and tert-butyl.
  • C ⁇ - 6 -alkyl represents a branched or linear alkyl group having from one to six carbon atoms.
  • Typical C ⁇ - ⁇ s alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, butyl, iso- butyl, sec-butyl, tert-butyl, pentyl, hexyl , and the like.
  • C 2 - 15 -alkenyl represents an branched or linear group having from two to fifteen carbon atoms and at least one double bond. Examples of such groups include, but are not limited to, 1-propenyl, 2-propenyl, 1-butenyl, hexenyl, pentenyl, hexenyl, heptenyl, octenyl, and the like.
  • C 2 - 5 -alkenyl represents an branched or linear group having from two to five carbon atoms and at least one double bond. Examples of such groups include, but are not limited to, 1-propenyl, 2-propenyl, 1- butenyl , pentenyl, 2 , 2-dimethylpropenyl , and the like.
  • C 2 -C 15 alkynyl • refers to an unsaturated branched or linear group having from two to fifteen carbon atoms and at least one triple bond.
  • Examples of such groups include, but are not limited to, 1-propynyl, 2-propynyl, 1- butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 1-hexynyl, 1- heptynyl, and the like.
  • C 2 - 5 -alkynyl refers to an unsaturated branched or linear group having from two to five carbon atoms and at least one triple bond. Examples of such groups include, but are not limited to, 1-propynyl, 2- propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, and the like.
  • C 3 -C 10 cycloalkyl represents cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, and cyclodecyl .
  • C 4 - 12 - (cycloalkylalkyl) refers to a C 3 -C 10 cycloalkyl linked to a "C ⁇ - 4 -alkyl group in such a manner that the total number of carbon atoms in the group is between 4 and 12.
  • Typical C - 2 - (cycloalkylalkyl) groups include cyclopropylmethyl, eye1opropylethyl , cyclopropylpropyl, cyclopropylbutyl, cyclobutylmethyl , cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylmethyl, 3-cyclopentylpropyl, and the like.
  • C ⁇ - 4 -alkoxy represents a branched or linear alkyl group having from one to four carbon atoms attached through and oxygen atom.
  • Typical C ⁇ - 4 -alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, iso-propoxy, butoxy, and the like.
  • pharmaceutically acceptable salts include the physiologically acceptable salts which are often used in pharmaceutical chemistry. Many such salts are described in Journal of Pharmaceutical Science, 66 , 2 (1977) . It will be understood by the skilled reader that some of the compounds used in the present invention are capable of forming salts, and that the salt forms of pharmaceuticals are commonly used, often because they are more readily crystallized and purified than are the free bases. In all cases, the use of the pharmaceuticals described above as salts is contemplated in the description herein, and often is preferred, and the pharmaceutically acceptable salts of all of the compounds are included in the names of them. It is- also understood that the term “pharmaceutically acceptable salts” refers to acid addition and base addition salts.
  • a pharmaceutically acceptable salt is formed from a pharmaceutically acceptable acid or a pharmaceutically- acceptable base as is well known in the art.
  • Typical inorganic acids used to form acid addition salts include hydrochloric, hydrobromic, hydriodic, nitric, sulfuric, phosphoric, hypophosphoric, metaphosphoric, pyrophosphoric, and the like.
  • Acid addition salts derived from organic acids, such as aliphatic mono and dicarboxylic acids, phenyl substituted alkanoic acids, hydroxyalkanoic and hydroxyalkandioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, may also be used.
  • Such pharmaceutically acceptable salts thus include acetate, phenylacetate, trifluoroacetate, acrylate, ascorbate, benzoate, chlorobenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, methylbenzoate , o-acetoxybenzoate, naphthalene-2-benzoate, isobutyrate, phenylbutyrate, hydroxybutyrate, butyne-1, 4-dicarboxylate, hexyne-1,4- dicarboxylate, caprate, caprylate, cinnamate, citrate, formate, fumarate, glycollate, heptanoate, hippurate, lactate, malate, maleate, hydroxymaleate, malonate, mandelate, mesylate, nicotinate, isonicotinate, nitrate, oxalate, phthalate, teraphthalate, propiolate, propionate, phenylpropionat
  • Intermediate 1 can be prepared using methods known to the skilled artisan. For example, the preparation of the Intermediate 1 is taught in US Patent No. 5,229,382.
  • a sub-surface nitrogen sparge line was added to remove the ammonia formed during the reaction.
  • the reaction was heated to 120°C and maintained at that temperature throughout the duration of the reaction.
  • the reactions were followed by HPLC until 5% of the intermediate 1 was left unreacted.
  • the mixture was allowed to cool slowly to 20°C (about 2 hours) .
  • the reaction mixture was then transferred to an appropriate three neck round bottom flask and water bath.
  • the reaction slurry was cooled to zero to 5°C and stirred for 30 minutes.
  • the product was filtered and the wet cake was washed with chilled methanol .
  • the wet cake was dried in vacuo at 45°C overnight.
  • the product was identified as technical olanzapine. Yield: 76.7%; Potency: 98.1%
  • the combination is usually administered in the form of pharmaceutical compositions.
  • the adjunctive therapy of the present invention is carried out by administering a first component together with the second component in any manner which provides effective levels of the compounds in the body at the same time.
  • Oral administration of the adjunctive combination is preferred. They may be administered together, in a single dosage form, or may be administered separately.
  • Oral administration is not the only route or even the only preferred route.
  • transdermal administration may be very desirable for patients who are forgetful or petulant about taking oral medicine.
  • One of the drugs may be administered by one route, such as oral, and the others may be administered by the transdermal, percutaneous, intravenous, intramuscular, intranasal or intrarectal route, in particular circumstances.
  • the route of administration may be varied in any way, limited by the physical properties of the drugs and the convenience of the patient and the caregiver.
  • the adjunctive combination may be administered as a single pharmaceutical composition, and so pharmaceutical compositions incorporating both compounds are important embodiments of the present invention.
  • Such compositions may take any physical form which is pharmaceutically acceptable, but orally usable pharmaceutical compositions are particularly preferred.
  • Such adjunctive pharmaceutical compositions contain an effective amount of each of the compounds, which effective amount is related to the daily dose of the compounds to be administered.
  • Each adjunctive dosage unit may contain the daily doses of all compounds, or may contain a fraction of the daily doses, such as one-third or one-half of the doses.
  • each dosage unit may contain the entire dose of one of the compounds, and a fraction of the dose of the other compounds.
  • the patient would daily take one of the combination dosage units, and one or more units containing only the other compounds.
  • the amounts of each drug to be contained in each dosage unit depends on the identity of the drugs chosen for the therapy, and other factors such as the indication for which the adjunctive therapy is being given.
  • compositions contain from about 0.5% to about 50% of the compounds in total, depending on the desired doses and the type of composition to be used.
  • the amount of the compounds is best defined as the effective amount, that is, the amount of each compound which provides the desired dose to the patient in need of such treatment .
  • adjunctive combinations do not depend on the nature of the composition, so the compositions are chosen and formulated solely for convenience and economy. Any of the combinations may be formulated in any desired form of composition. Some discussion of different compositions will be provided, followed by some typical formulations.
  • Capsules are prepared by mixing the compound with a suitable diluent and filling the proper amount of the mixture in capsules.
  • the usual diluents include inert powdered substances such as starch of many different kinds, powdered cellulose, especially crystalline and microcrystalline cellulose, sugars such as fructose, mannitol and sucrose, grain flours and similar edible powders .
  • Tablets are prepared by direct compression, by wet granulation, or by dry granulation. Their formulations usually incorporate diluents, binders, lubricants and disintegrators as well as the compound. Typical diluents include, for example, various types of starch, lactose, mannitol, kaolin, calcium phosphate or sulfate, inorganic salts such as sodium chloride and powdered sugar. Powdered cellulose derivatives are also useful. Typical tablet binders are substances such as starch, gelatin and sugars such as lactose, fructose, glucose and the like. Natural and synthetic gums are also convenient, including acacia, alginates, methylcellulose, polyvinylpyrrolidone and the like. Polyethylene glycol, ethylcellulose and waxes can also serve as binders.
  • a lubricant is necessary in a tablet formulation to prevent the tablet and punches from sticking in the die .
  • the lubricant is chosen from such slippery solids as talc, magnesium and calcium stearate, stearic acid and hydrogenated vegetable oils.
  • Hard gelatin capsules are prepared using the following ingredients :
  • a tablet is prepared using the ingredients below: Quantity (mg/tablet)
  • the components are blended and compressed to form tablets.
  • Conditioned Avoidance Behavior in Rats In a conditioned avoidance test, animals learn to respond during a conditioned stimulus in order to avoid mild shock presentation. A response during the conditioned stimulus is termed an avoidance response, a response during shock is termed an escape response; a response failure is when the animal fails to respond during either the conditioned stimulus or the shock presentation and is indicative of motor impairment. Animals rapidly learn to avoid 99% of the time. Antipsychotic drugs decrease the percentage of avoidance responses without interfering with the ability of the animal to respond since the animals do emit escape responses . The percentage of response failures is considered a measure of motor impairment. Procedure :
  • Rats were required to press a response lever in an experimental chamber in order to avoid or escape foot-shock.
  • Each experimental session consisted of 50 trials. During each trial, the chamber was illuminated and a tone presented for a maximum of 10 sec. A response during the tone immediately terminated the tone and the houselight, ending the trial . In the absence of a response during the tone alone, tone+foot-shock (2.0 mA) was presented for a maximum of 10 sec. A response during shock presentation immediately terminated the shock, the tone and the houselight, ending the trial.
  • the synergistic effects of the present combinations can be demonstrated by administering an inactive or relatively inactive dose of one component (such as the selected muscarinic agonist) and various doses of the other component. If the effects are simply additive the results will be additive. If the effects of are synergistic, then the dose of second component required to produce full efficacy will be decreased. In particular, if the dose of both components are inactive when administered alone, but produce full efficacy when given in combination, then the combination is synergistic.
  • one component such as the selected muscarinic agonist

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides combination therapy comprising a first component which is a typical antipsychotic or an atypical antipsychotic and a second component which is a muscarinic agonist for the treatment of psychoses and other disorders.

Description

COMBINATION THERAPY FOR TREATMENT OF PSYCHOSES
The present invention belongs to the fields of pharmacology, medicine, and medicinal chemistry, and provides methods and compositions for the treatment of a disorders, including psychoses.
BACKGROUND OF THE INVENTION
Psychoses are serious mental illnesses characterized by defective reality or lost contact with reality. Psychotic patients may suffer hallucinations, delusions, and grossly disorganized behavior as part of their disease. Psychoses exact a tremendous emotional and economic toll on the patients, their families, and society as a whole. For example, it has been estimated that as many as 50% of the homeless people living in the United States are psychotic. (Bachrach, Treating the Homeless Mentally 111, Washington, D.C., American Psychiatric Press, 1340, Lamb et al . ed. (1992)). In addition, approximately 2.5% of the total dollars spent for health care in the United States is spent in the treatment of psychoses (Rupp et al . , Psychiatric Clin. North Am. , 16:413-423 (1993)).
Several classes of compounds are useful for treating psychotic disorders. The drugs available for such conditions are often associated with undesirable side effects.
Furthermore, many patients do not respond or only partially respond to present drug treatment, and estimates of such partial-responders and non-responders vary between 40% and 80% of those treated. Thus, further methods of treating psychoses are highly desirable.
The present invention addresses these needs by providing a method of treating psychosis, and other disorders as described herein, by the synergistic effect of combination therapy of a typical or atypical antipsychotic and a muscarinic agonist. SUMMARY OF THE INVENTION
The invention provides a method for treating a patient suffering from or susceptible to psychosis, comprising administering to the patient an effective amount a first component which is a typical antipsychotic or an atypical antipsychotic and an effective amount of a second component which is a muscarinic agonist.
The invention also provides a pharmaceutical composition which comprises a first component which is a typical antipsychotic or an atypical antipsychotic, and a second component which is a muscarinic agonist.
That is, the present invention provides the use of a pharmaceutical composition comprising an effective amount of a first component which is a typical antipsychotic or an atypical antipsychotic, in combination with an effective amount of a second component which is a muscarinic agonist for treating psychosis.
DETAILED DESCRIPTION OF THE INVENTION The present invention provides for treatment for patients suffering from psychosis comprising the administration of a typical antipsychotic or an atypical antipsychotic and a muscarinic agonist. It has been discovered that the administration of a typical antipsychotic or an atypical antipsychotic and a muscarinic agonist unexpectedly enhances the therapeutic effect of the combination. That is, the combined administration of a typical antipsychotic or an atypical antipsychotic and a muscarinic agonist provides a synergistic effect. Thus, the combination therapy of the present invention provides an effective treatment of psychoses with lessened side effects and of broader applicability than each of the individual components alone.
Within the context of the present invention, the term "psychosis" includes schizophrenia, schizophreniform diseases, mania, schizoaffective disorders, and depression with psychotic features. The above mentioned conditions represent multiple disease states. For example, schizophrenia is referred to in various forms as catatonic, disorganized, paranoid, undifferential, residual, among others. All the various forms of the disorders mentioned herein are contemplated as part of the present invention. The following list further illustrates a number of these disease states, many of which are classified in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, published by the American Psychiatric Association (DSM IV) : Paranoid Type Schizophrenia, Disorganized Type Schizophrenia, Catatonic Type Schizophrenia, Undifferentiated Type Schizophrenia, Residual Type Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder, Psychotic Disorder Due to a General Medical Condition, Substance-Induced Psychotic Disorder, Psychotic Disorder Not Otherwise Specified, Major Depressive Disorder with Psychotic Features, Bipolar Disorder I, Bipolar Disorder II, Bipolar Disorder Not Otherwise Specified, Schizoid Personality Disorder, and
Schitzotypal Personality Disorder.
In addition, other disorders that are treated by the present combination include, dementia, including Alzheimer's disease, mood disorders, including depression, anxiety disorders, including general anxiety disorder and panic disorder, adjustment disorders, decreased cognition.
All of these disorders are readily diagnosed by the skilled clinician using well established criteria, including those in the DSM IV. In particular, a patient suffering from or susceptible to psychosis can be readily diagnosed using the methods described in the DSM-IV and other criteria known in the art .
As will be appreciated by the skilled person, there are alternative nomenclatures, nosologies, and classification systems for the psychoses described herein and that these systems evolve with medical scientific progress. Applicants do not intend that the present invention be limited to any disorders literally mentioned in the DSM-IV.
The term "patient" refers to a mammal and includes, mice, rats, dogs, sheep, cattle, pigs, guinea pigs, cats, chimpanzees, monkeys, apes, and humans, etc. In particular the term includes a human suffering from psychosis.
The term "effective amount of a first component" and "an effective amount a second component" refers to the amounts of typical antipsychotic or an atypical antipsychotic and amounts of a muscarinic agonist, respectively, which, upon single or multiple administration to the patient, is synergistically effective in alleviating or controlling the disorders described herein, and in particular psychosis. An effective amount of a first component and an effective amount of a second component can be readily determined by the attending diagnostician, as one skilled in the art, by the use of conventional techniques and by observing results.. In determining an effective amount of the first and second components a number of factors are considered by the attending diagnostician, including, but not limited to: the properties of the individual components, the properties of the components in combination as determined in preclinical and clinical trials, the dose of each component, the species of mammal; its size, age, and general health; the specific disorder (s) involved; the degree of involvement or the severity of the disorder (s) ; the response of the individual patient; the mode of administration; the bioavailability of the formulation administered; the dose regimen selected; and other factors known in the art .
Some preferred dosages are provided here for dosing of the combination of xanomeline and olanzapine : xanomeline, from about 1 to 225 mg per day, preferred; and most preferably about 25 to 125 mg per day; and for olanzapine from about 0.25 to 50 mg, once/day; preferred, from 1 to 30 mg, once/day; and most preferably 1 to 25 mg once/day. The class of compounds referred to a "typical antipsychotic" are effective in improving symptoms of psychoses, and in particular schizophrenia, by acting as dopamine receptor antagonists, more particularly D dopamine receptor antagonists, which also are known as D2 dopamine receptor blockading agents. As used herein, the term "typical antipsychotic" include those drugs known as typical neuroleptics .
As used herein the term "typical antipsychotic" includes, but is not limited to, thiopropazate, chlorpromazine, triflupromazine, esoridazine, piperacetazine, thioridazine, acetophenazine, fluphenazine, perphenazine, trifluoperazine, chlorprathixene, thiothixene, haloperidol , bromperidol, loxapine, molindone, loxapine, molindone, and pimozide. These compound are well known in the art .
The class of compounds referred to a "atypical antipsychotic" are effective in improving symptoms of psychoses, and in particular schizophrenia. These compounds act be a variety of mechanisms, including antagonism of D2, D3 and D4 dopamine neurons, 5-HT2 receptors, and an alpha2- adrenergic receptors. As used herein, the term "atypical antipsychotic" include those drugs known as atypical neuroleptics . As used herein the term "atypical antipsychotic" includes, but is not limited to, clozapine, 8-chloro-ll- (4- methyl-1-piperazinyl) -5H-dibenzo [b, e] [1, 4] diazepine (U.S. Patent No. 3,539,573); olanzapine, 2-methyl-4- (4-methyl-1- piperazinyl) -lOH-thieno [2, 3-b] [1, 5] benzodiazepine (U.S. Patent No. 5,229,382); zotepine, iloperidone, amisulpiride perospirone, risperidone, 3- [2- [4- (6-fluoro-1, 2- benzisoxazol-3-yl)piperidino] ethyl] -2 -methyl-6, 7,8,9- tetrahydro-4H-pyrido [1, 2-a] pyrimidin-4-one (U.S. Patent No. 4,804,663); and sertindole, 1- [2- [4- [5-chloro-l- (4- fluorophenyl) -lH-indol-3-yl] -1-piperidinyl] ethyl] imidazolidin-2-one (U.S. Patent Nos . 4,710,500; 5,112,838; 5,238,945); quetiapine, 5- [2- (4-dibenzo [b, f] [1, 4] thiazepin- 11-yl-1-piperazinyl) ethoxy] ethanol (U.S. Patent No. 4,879,288); and ziprasidone, 5- [2- [4- (1, 2-benzoisothiazol-3- yl) -1-piperazinyl] ethyl] -6-chloro-l, 3-dihydro-2H-indol-2-one (U.S. Patent Nos . 4,831,031 and 5,312,925). These compound are also well known in the art .
The class of compounds referred to as "muscarinic agonists" are effective in improving symptoms of psychoses, and in particular schizophrenia. As used herein the term "muscarinic agonist" includes, but is not limited to, pilocarpine, oxotre orine, bethanechol , carachol , sabcomeline, milameline, talsaclidine, and the compounds of the formula I, II, and III below:
Figure imgf000007_0001
wherein
W is oxygen or sulfur;
R is selected from the group consisting of -OR4, -SR4,
-Z-C3-ιo-cycloalkyl and -Z-C4-12- (cycloalkylalkyl) ; R4 is selected from the group consisting of C - s-alkyl,
C2-15 _alkenyl and C2-i5-alkynyl, each of which is optionally substituted with one or more independently selected from the group consisting of halogen(s), -CF3, -CN, C -4-alkoxy, phenyl, and phenoxy wherein the phenyl or phenoxy is optionally substituted with one or more independently selected from the group consisting of halogen, -CN, Cι_4-alkyl, C -^-alkoxy, -OCF3, -CF3, -CONH2 and -CSNH2; Z is oxygen or sulphur; Z2 is oxygen or sulphur
G is selected from the group consisting of:
Figure imgf000008_0001
R1 and R2 independently are selected from the group consisting of hydrogen, Cι_i5-alkyl, C2-5-alkenyl, C2-5- alkynyl, C _ιo-alkoxy, and Cι_5-alkyl substituted with one or more independently selected from the group consisting of -OH, -COR6, CH2-OH, halogen, -NH2, carboxy, and phenyl;
R6 is hydrogen, Ci-g-alkyl;
R3 is selected from the group consisting of hydrogen,
C -5-alkyl, C2-5-alkenyl and C2-5~alkynyl ; n is 1 or 2, m is 1 or 2 p is 1 or 2 q is 1 or 2 r is 0, 1 or 2; or a pharmaceutically acceptable salt thereof;
Figure imgf000008_0002
R5 is selected from the group consisting of -OR4, -SR4, R4 is selected from the group consisting of Cι_15-alkyl, C2-i5~alkenyl and C2-i5-alkynyl, each of which is optionally substituted with one or more independently selected from the group consisting of halogen (s), -CF3, -CN, Cι-4-alkoxy, phenyl, and phenoxy wherein the phenyl or phenoxy is optionally substituted with one or more independently selected from the group consisting of halogen, -CN, Ci-4-alkyl, Cι_4-alkoxy, -OCF3, -CF3, -CONH2 and -CSNH2; Zx is oxygen or sulphur,
R7 is selected from the group consisting of hydrogen, cι-i5~alkyl, C2-5~alkenyl, C2-5~alkynyl ;
R8 is selected from the group consisting of hydrogen, and Cι-4-alkyl; or a pharmaceutically acceptable salt thereof;
Figure imgf000009_0001
W is oxygen or sulfur;
R is selected from the group consisting of -OR4, -SR4, -Z-C3_ιo-cycloalkyl and -Z-C4_i2~ (cycloalkylalkyl) ;
R4 is selected from the group consisting of Cι_ 5-alkyl, c 2-15 _alkenyl and C2-i5-alkynyl , each of which is optionally substituted with one or more independently selected from the group consisting of haloge (s), -CF3, -CN, Cι-4-alkoxy, phenyl, and phenoxy wherein the phenyl or phenoxy is optionally substituted with one or more independently selected from the group consisting of halogen, -CN, Cχ-4-alkyl, Cι_4-alkoxy, -OCF3, -CF3, -CONH2 and -CSNH2; Z is oxygen or sulphur,
G is selected from the group consisting of:
Figure imgf000010_0001
R1 and R2 independently are selected from the group consisting of hydrogen, Cι-15-alkyl , C2-5~alkenyl , C2-5- alkynyl, Cι-10-alkoxy, and Cι-5-alkyl substituted with one or more independently selected from the group consisting of -OH, -COR6, CH2-OH, halogen, -NH2, carboxy, and phenyl; R6 is hydrogen, Cι-6-alkyl;
R3 is selected from the group consisting of hydrogen, Cχ-5-alkyl, C2-5-alkenyl and C2-5~alkynyl ; n is 1 or 2 m is 1 or 2; p is 1 or 2 q is 1 or 2 r is 0, 1 or 2; or a pharmaceutically acceptable salt thereof.
The compounds of formula I, II, and III are readily prepare according to the methods described in U.S. Patent Nos. 5,043,345; 5,968,926; 5, 744,489; and 5,998,404. Preferred compounds of formula I are (+) 3-{3- [4- (trifluoromethyl) phenyl] propylthio} -4- [-3- (1- azabicyclo [2.2.2] octyloxy) ] -1,2, 5-thiadiazole, (±) -3- Methoxy-4- (1-azabicyclo [2.2.2] octyl-3-oxy) -1,2,5- thiadiazole, (±) -3-Ethoxy-4- (1-azabicyclo [2.2.2] octyl-3- oxy) -1,2, 5-thiadiazole, (+) -3-Propyloxy-4- (1- azabicyclo [2.2.2] octyl-3-oxy) -1, 2, 5-thiadiazole, (+) -3- Butyloxy-4- (1-azabicyclo [2.2.2] octyl-3-oxy) -1,2,5- thiadiazole, (±) -3-Pentyloxy-4- (1-azabicyclo [2.2.2] octyl- 3-oxy) -1,2, 5-thiadiazole, (+) -3-Hexyloxy-4- (1- azabicyclo [2.2.2] octyl-3-oxy) -1,2, 5-thiadiazole, (+) -3- (4-Methylpentyloxy) -4- (1-azabicyclo [2.2.2] octyl-3-oxy) - 1,2, 5-thiadiazole, (+) -3-Propylthio-4- (1- azabicyclo [2.2.2] octyl-3-oxy) -1,2, 5-thiadiazole, (±) -3- Butylthio-4- (1-azabicyclo [2.2.2] octyl-3-oxy) -1,2,5- thiadiazole, (±) -3-Pentylthio-4- (1-azabicyclo [2.2.2] octyl- 3-oxy) -1,2, 5-thiadiazole, (S) -3-Pentylthio-4- (1- azabicyclo [2.2.2] octyl-3-oxy) -1,2, 5-oxadiazole,
(±) -3-Hexylthio-4- (1-azabicyclo [2.2.2] octyl-3-oxy) - 1,2, 5-thiadiazole, (+) -3- (2,2,3,3, 3-Pentafluoropropylthio) - 4- (1-azabicyclo [2.2.2] octyl-3-oxy) -1,2, 5-thiadiazole, (+) -3- Butylthio-4- ( (1-azabicyclo [2.2.2] octan-3 -yl) methoxy) -1,2,5- thiadiazole, (±) -Exo-3-pentylthio-4- (1- azabicyclo [3.2.1] octyl-6-oxy) -1,2, 5-thiadiazole, (+) -Endo-3- pentylthio-4- (1-azabicyclo [3.2.1] octyl-6-oxy) -1,2,5- thiadiazole, (±) -Endo-3-butyloxy-4- (1- azabicyclo [2.2.1] heptyl-3-oxy) -1,2, 5-thiadiazole, (±) -Exo-3- butyloxy-4- (1-azabicyclo [2.2.1] heptyl-3-oxy) -1,2,5- thiadiazole, (+) -3-Butyloxy-4- (3-pyrrolidinyloxy) -1,2,5- thiadiazole, (±) -3-Butyloxy-4- (1-methyl-3 -pyrrolidinyloxy) - 1,2, 5-thiadiazole, (±) -3 -Butylthio-4- (1-methyl-3- piperidyloxy) -1, 2, 5-thiadiazole, 3 -Butylthio-4- (l-methyl-4- piperidyloxy) -1,2, 5-thiadiazole, (S) -3-Butyloxy-4- (1-methyl- 2-pyrrolidinylmethoxy) -1, 2 , 5-thiadiazole, (S) -3-Butyloxy-4- (2 -pyrrolidinylmethoxy) -1, 2 , 5-thiadiazole, (R) -3-Pentylthio- 4- (1-azabicyclo [2.2.2] octyl-3-oxy) -1,2, 5-thiadiazole, (±) -3- (4-Methylpentylthio) -4- (1-azabicyclo [2.2.2] octyl-3-oxy) - 1,2, 5-thiadiazole, (+) -3- (3-Phenylpropylthio) -4- (1- azabicyclo [2.2.2] octyl-3-oxy) -1,2, 5-thiadiazole, (±) -3- (4- Cyanobenzylthio) -4- (1-azabicyclo [2.2.2] octyl-3-oxy) -1,2,5- thiadiazole, (±) -3- (4-Fluorobenzylthio) -4- (1- azabicyclo [2.2.2] octyl-3-oxy) -1,2, 5-thiadiazole, (±) -3- (2- Phenylethylthio) -4- (1-azabicyclo [2.2.2] octyl -3-oxy) -1,2,5- thiadiazole, (±) -3- (2-Phenyloxyethylthio) -4- (1-
Figure imgf000012_0001
tetrahydropyridine; 3- (3-Ethoxy-l, 2 , 5-thiadiazol-4-yl) -1- ethyl-1, 2,5, 6-tetrahydropyridine; 3- (3-Heptyloxy-l, 2 , 5- thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (3-Pentynyloxy) -1,2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l- methylpyri dine; 3- (3- (4-Pentenyloxy) -1, 2 , 5-thiadiazol-4- yl) -1, 2 , 5, 6-tetrahydro-l-methylpyri dine; 3- (3- (2- Propenyloxy) -1,2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l- methylpyri dine; 3- (3-Octyloxy-l, 2 , 5-thiadiazol-4-yl) - 1, 2 , 5 , 6-tetrahydro-l-methylpyridine; 3- (3- (3-Hexynyloxy) - 1,2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l- methylpyridine; 3- (3- (3-Methyl-2-butenyloxy) -1,2,5- thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (3-Butenyl-2-oxy) -1,2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro- l-methylpyridine; 3- (3- (4-Hexenyloxy) -1, 2 , 5-thiadiazol-4- yl) -1,2 , 5, 6-tetrahydro-l-methylpyridine; trans-3- (3- (3- Hexenyloxy) -1,2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l- methy-1-pyridine; cis-3- (3- (2-Pentenyloxy) -1,2, 5-thiadiazol- 4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; cis-3- (3- (2- Hexenyloxy) -1,2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l- methylpyridine; 3- (3- (5-Hexenyloxy) -1, 2 , 5-thiadiazol-4-yl) - 1,2,5, 6-tetrahydro-l-methylpyridine; cis-3- (3- (3- Hexenyloxy) -1,2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l- methylpyridine; trans-3- (3- (2-Hexenyloxy) -1, 2 , 5-thiadiazol- 4-yl) -1,2,5, 6-tetrahydro-l-methy-l-pyridine; ,2,5,6- Tetrahydro-3- (3-hexyloxy-l, 2, 5-thiadiazol-4- yl)pyridine; 1,2,5, 6-Tetrahydro-3- (3 -methoxy-1, 2,5- thiadiazol-4-yl) -1, 4-dimethylpyridine; 3- (3-Hexyloxy-l, 2, 5- thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l, 4-dimethylpyridine; 3- (3-Hexyloxy-l, 2 , 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l, 6- dimethylpyridine ; 3- (3-Pentyloxy-l, 2 , 5-thiadiazol-4-yl) -
1,2,5, 6-tetrahydro-l, 6-dimethylpyridine; 3- (3-Butoxy-l, 2 , 5- thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l, 6-dimethylpyridine; 3- (3- (4-Pentenyloxy) -1, 2 , 5-thiadiazol-4-yl) -1,2,5,6- tetrahydro-1, 6-dimethylpyridine; 3- (3- (3-Hexynyloxy) -1,2,5- thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l, 6-dimethylpyridine; 3- (3-Ethoxy-l, 2 ,5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l, 6- dimethylpyridine ; 3- (3- (1-Ethylpentyloxy) -1, 2 , 5-thiadiazol- 4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (1- Ethylbutoxy) -1,2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l- methylpyri dine; 3- (3- (1-Methylpentyloxy) -1, 2 , 5-thiadiazol - 4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (5- Hexynyloxy) -1,2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l- methylpyridine; 3- (3- (3-Methyl-4-pentenyloxy) -1,2,5- thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (2 , 3-Dimethylpentyloxy) -1,2, 5-thiadiazol-4-yl) -1,2,5,6- tetrahydro-1-methylpyridine; 3- (3- (4-Methylhexyloxy) -1,2,5- thiadiazol-4-yl) -1, 2 , 5, 6-tetrahydro-l-methylpyridine; 3- (3- (1-Methylhexyloxy) -1,2, 5-thiadiazol-4-yl) -1,2,5,6- tetrahydro-1-methylpyridine; 3- (3- (3-Methylpentyloxy) -1,2,5- thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- Isoheptyloxy-1, 2 , 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l- methylpyridine; 3- (3-Isohexyloxy-l, 2 , 5-thiadiazol-4-yl) - 1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3-Hexyloxy-l, 2,5- thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l-ethylpyridine; 3- (3- Ethoxy-1, 2 , 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydropyridine; 3- (3-Cyclopropylmethoxy-l, 2 , 5-thiadiazol-4-yl) -1,2,5,6- tetrahydro-1-methylpyridine; 1, 2 , 5 , 6-Tetrahydro-3- (3- methoxyethoxy-1, 2, 5-thiadiazol-4-yl) -1-methylpyridine; 3- (3- (2- (2-Methoxyethoxy)ethoxy) -1, 2 , 5-thiadiazol-4-yl) - 1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (3-Ethoxy-l- propoxy) -1,2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methy 1-pyridine; 3- (3- (2-Ethoxyethoxy) -1, 2 , 5-thiadiazol-4-yl) -
1, 2 , 5, 6-tetrahydro-l-methylpyridine; 3- (3- (2-Butoxyethoxy) - 1,2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (2- (2-Butoxyethoxy) ethoxy) -1, 2 , 5-thiadiazol-4-yl) - 1,2,5, 6-tetrahydro-l-methylpyridine; 1,2,5, 6-Tetrahydro-1- methyl-3- (3- (6, 6, 6-trifluorohexyloxy) -1, 2 , 5-thiadiazol -4- yl)pyridine; 1,2,5, 6-Tetrahydro-l-methyl-3- (3- (3- (4- methoxyphenyl) -1-propoxy) -1,2,5-thia diazol-4-yl)pyridine; 1,2,5, 6-Tetrahydro-l-methyl-3- (3- (2- (4-methoxyphenyl) -1- ethoxy) -1, 2, 5-thiad iazol-4-yl) pyridine; 1, 2 , 5, 6-Tetrahydro- 1-methyl-3- (3- (3 -hydroxy-1-propoxy) -1,2, 5-thiadiazol-4- yl) pyridine; 1,2,5, 6-Tetrahydro-1-methyl-3- (3- (2 -phenyl-1- ethoxy) -1,2, 5-thiadiazol-4-yl) pyridine; 1,2,5, 6-Tetrahydro- 1-methyl-3- (3- (3-hydroxy-l-hexyloxy) -1,2, 5-thiadiazol-4- yl) pyridine; 1,2,5, 6-Tetrahydro-l-methyl-3- (3- (3 -phenyl-1- propoxy) -1, 2, 5-thiadiazol-4-yl ) pyridine; 1,2,5,6- Tetrahydro-l-methyl-3- (3- (6-acetamido-l-hexyloxy) -1,2,5- thiadiazol- 4-yl) pyridine; 1, 2 , 5, 6-Tetrahydro-1-methyl -3- (3 - (2-acetamido-l-ethoxy) -1,2, 5-thiadiazol-4-yl) pyridine; 1,2,5, 6-Tetrahydro-1-methyl -3- (3- (2-propionamido-l-ethoxy) - 1, 2 , 5-thiadiazol -4-yl) pyridine; 1, 2 , 5, 6-Tetrahydro-1- methyl-3- (3- (2 -benzylthio-1-ethoxy) -1,2, 5-thiadiazol-4 - yl)pyridine; 1, 2 , 5, 6-Tetrahydro-1-methyl-3- (3- (2-ureido-l- ethoxy) -1, 2 , 5-thiadiazol -4-yl) pyridine; 3- (3- (4- Fluorophenylpropoxy) -1,2, 5-thiadiazol-4-yl) -1,2,5,6- tetrahydro-1-methylpyridine; 3- (3- (4-Chlorophenylpropoxy) - 1,2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (3-Methylphenylpropoxy) -1,2, 5-thiadiazol-4-yl) -1,2,5,6- tetrahydro-1 -methylpyridine; 3- (3- (4-Methylphenylpropoxy) - 1,2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3 -Phenylbutoxy-1, 2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro- l-methylpyridine; 3- (3- (2-Methylphenylpropoxy) -1, 2, 5- thiadiazol-4-yl) -1, 2 , 5, 6-tetrahydro-1-methylpyridine;
3- (3- (2, 5-Dimethylphenylpropoxy) -1,2, 5-thiadiazol-4-yl) - 1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (3,4- Dichlorophenylpropoxy) -1,2, 5-thiadiazol-4-yl) -1,2,5,6- tetrahydro-1-methylpyridine; 3- (3- (4-Methylphenylpropoxy) - 1,2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (4-Cyclohexylbutoxy) -1,2, 5-thiadiazol-4-yl) -1,2,5,6- tetrahydro-l-methy-1-pyridine; 3- (3- (5-Hydroxyhexyloxy) - 1,2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (5-Oxyhexyloxy) -1, 2 , 5-thiadiazol-4-yl) -1,2,5,6- tetrahydro-1-methylpyridine; 3- (3- (3-Cyclohexenylmethoxy) - 1,2 , 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3-Isobutylthioethoxy-l,2, 5-thiadiazol-4-yl) -1,2,5,6- tetrahydro-1-methylpyridine; 3- (3-Cyclopropylpropoxy-l, 2 , 5- thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (2-Methylcyclopropylmethoxy) -1,2, 5-thiadiazol-4-yl) - 1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- Cyclopentylpropyloxy-1, 2 , 5-thiadiazol-4-yl) -1,2,5,6- tetrahydro-1-methylpyridine; 3- (3- (4, 4 , -Trifluorobutoxy) - 1,2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (6, 6, 6-Trifluorohexyloxy) -1,2, 5-thiadiazol-4-yl) - 1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (3- Cyclobutylpropoxy) -1,2, 5-thiadiazol-4-yl) -1,2,5,6- tetrahydro-1-methylpyridine; 3- (3-Isopropoxyethoxy-l, 2 , 5- thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (2,2,2-Trifluoroethoxy) -1, 2 , 5-thiadiazol-4-yl) -1,2,5,6- tetrahydro-1-methylpyridine; 3- (3- (2-Chlorophenylpropoxy- 1,2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (3-Cyclohexylpropoxy) -1,2, 5-thiadiazol-4-yl) -1,2,5,6- tetrahydro-1-methylpyridine; 3- (3- (2-Cyclohexylethoxy) - 1,2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (2,2,2-Trifluoroethoxy) -1, 2 , 5-thiadiazol-4-yl) -1,2,5,6- tetrahydropyridine; 3- (3- (3-Carboxypropoxy) -1, 2 , 5- thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3-Benzyloxy-1, 2 , 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l- methylpyridine; 3- (3- (4-Ethylbenzyloxy) -1, 2 , 5-thiadiazol-4- yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (4- Butylbenzyloxy) -1,2 , 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l- methylpyridine; 3- (3-Propylthio-1, 2 , 5-thiadiazol-4-yl) - 1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3-Butylthio-l, 2,5- thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- Methylthio-1, 2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-1- methylpyridine; 3- (3-Octylthio-l, 2 , 5-thiadiazol-4-yl) -
1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3-Ethylthio-l, 2,5- thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- Pentylthio-1, 2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l- methylpyridine; 3- (3-Hexylthio-l, 2, 5-thiadiazol-4-yl) - 1,2, 5, 6-tetrahydro-l-methylpyridine; 3- (3-Hexylthio-l , 2 , 5- thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l, 6-dimethylpyridine; 3- (3-Pentylthio-l, 2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro- 1, 6-dimethylpyridine; 3- (3-Butylthio-l, 2 , 5-thiadiazol-4-yl) - 1,2,5, 6-tetrahydro-l, 6-dimethylpyridine; 3- (3-Ethylthio- 1,2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l, 6- dimethylpyridine; 3- (3- (4-Pentynylthio) -1, 2 , 5-thiadiazol-4- yl) -1,2,5, 6-tetrahydro-l, 6-dimethy-1-pyridine; 3- (3- Hexylthio-1, 2 , 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-1- ethylpyridine; 3- (3-Ethylthio-l, 2, 5-thiadiazol-4-yl) - 1,2,5, 6-tetrahydro-1-ethylpyridine; 3- (3-Ethylthio-l, 2,5- thiadiazol-4-yl) -1,2,5, 6-tetrahydropyridine; 3- (3- Propylthio-1, 2 , 5-thiadiazol-4-yl) -1,2,5,6- tetrahydropyridine; 3- (3-Butylthio-l, 2 , 5-thiadiazol-4-yl) - 1,2,5, 6-tetrahydropyridine; 3- (3-Pentylthio-l, 2 , 5- thiadiazol-4-yl) -1, 2 , 5 , 6-tetrahydropyridine; 3- (3-Hexylthio- 1,2, 5-thiadiazol-4-yl-l, 2,5, 6-tetrahydropyridine; 3- (3- (4- Pentynylthio) -1, 2, 5-thiadiazol-4-yl) -1,2,5,6- tetrahydropyridine; 3- (3-Isohexylthio-l, 2 , 5-thiadiazol-4- yl) -1, 2, 5, 6-tetrahydro-l-methylpyridin e; cis-3- (3- (3- Hexenylthio) -1,2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l- methylpyridine; 3- (3- (5-Hexenylthio) -1, 2 , 5-thiadiazol-4-yl) - 1, 2 , 5, 6-tetrahydro-l-methylpyridine; 3- (3-Cyclopentylthio- 1,2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (4 -Pentynylthio) -1, 2 , 5-thiadiazol -4-yl) -1,2,5,6- tetrahydro-1-methylpyridine; 3- (3-Heptylthio-l, 2 , 5- thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (7-Octenylthio) -1, 2 , 5-thiadiazol-4-yl) -1,2, 5 , 6-tetrahydro-l- methylpyridine; 3- (3- (3-Butenylthio) -1, 2 , 5-thiadiazol-4-yl) - 1, 2 , 5, 6-tetrahydro-l-methylpyridine; 3- (3- (4-Pentenylthio) - 1,2 , 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (5-Cyanopentylthio) -1, 2 , 5-thiadiazol-4-yl) -1,2,5,6- tetrahydro-1-methylpyridine; 3- (3- (3-Chloropropylthio) -
1,2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (3-Cyanopropylthio) -1, 2 , 5-thiadiazol-4-yl) -1,2,5,6- tetrahydro-1-methylpyridine; 3- (3- (3-Phenylpropylthio) - 1,2, 5-thiadiazol -4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (2-Phenoxyethylthio) -1, 2 , 5-thiadiazol-4-yl) -1,2,5,6- tetrahydro-1-methylpyridine; 3- (3- (4-Cyanobutylthio) -1,2,5- thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (8-Hydroxyoctylthio) -1,2, 5-thiadiazol-4-yl) -1,2,5,6- tetrahydro-1-methylpyridine; 3- (3- (4-Chlorobutylthio) -1,2,5- thiadiazol-4-yl) -1, 2, 5, 6-tetrahydro-l-methylpyridine; 3-(3- (4,4-Bis- (4-fluorophenyl) -butylthio) -1,2, 5-thiadiazol-4-yl) - 1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (2- Phenylethylthio) -1,2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro- l-methylpyridine; 3- (3- (2-Benzoylethylthio) -1,2,5- thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methy-l-pyridine; 3- (3- (4,4,4-Trifluorobutylthio) -1, 2 , 5-thiadiazol-4-yl) - 1, 2 , 5, 6-tetrahydro-l-methylpyridine; 3- (3- (5,5,5-
Trifluoropentylthio) -1,2, 5-thiadiazol-4-yl) -1,2,5,6- tetrahydro-1-methylpyridine; 3- (3- (6,6,6- Trifluorohexylthio) -1,2, 5-thiadiazol-4-yl) -1,2,5,6- tetrahydro-1-methylpyridine; 3- (3-Ethoxycarbonylpentylthio- 1,2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (4-Cyanobutylthio) -1,2, 5-thiadiazol-4-yl) -1,2,5,6- tetrahydro-1, 6-dimethylpyridine; 3- (3- (3-Phenylpropylthio) - 1,2, 5-thiadiazol -4-yl) -1,2,5, 6-tetrahydro-l, 6- dimethylpyridine ; 3- (3- (2,2, 2-Trifluoroethylthio) -1,2,5- thiadiazol-4-yl) -1, 2, 5, 6-tetrahydropyridine; 3- (3- (2- Phenoxyethylthio) -1,2, 5-thiadiazol-4-yl) -1,2,5,6- tetrahydropyridine; 3- (3- (2 , 2 , 2 -Trifluoroethylthio) -1,2,5- thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- Ethoxycarbonylpropylthio-1, 2 , 5-thiadiazol-4-yl) -1,2,5,6- tetrahydro-1-methylpyridine; 3- (3- (6-Hydroxyhexylthio) - 1,2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-1-methy-1- pyridine; 3- (3- (1-Cyclopropylmethylthio) -1, 2 , 5-thiadiazol-4- yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (2- Methoxyethylthio) -1,2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro- 1-methy-l-pyridine; 3- (3- (2- (2-Ethoxymethoxy) -ethylthio) -
1,2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahy dro-1-methylpyridine; 3- (3- (2-Ethylbutylthio) -1, 2 , 5-thiadiazol-4-yl) -1,2,5,6- tetrahydro-1-methylpyridine; 3- (3-Cyclohexylmethylthio- 1,2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-1-methy-1- pyridine; 3- (3- (3,3, 3 -Trifluoropropylthio) -1,2, 5-thiadiazol- 4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (1-Oxo-l- phenylpropylthio-1, 2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro- l-methylpyridine; 3- (3- (4-Phenylthiobutylthio) -1,2,5- thiadiazol-4-yl) -1, 2, 5, 6-tetrahydro-l-methylpyridine; 3-(3- Cyanomethylthio-1, 2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l- methylpyridine; 3- (3- (6-Chlorohexylthio) -1, 2 , 5-thiadiazol-4- yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (5- Chloropentylthio) -1,2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro- 1-methy-l-pyridine; 3- (3- (3-Carboxypropylthio) -1,2,5- thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (5-Carboxypentylthio) -1,2, 5-thiadiazol-4-yl) -1,2,5,6- tetrahydro-1-methylpyridine; 3- (3- (5-Mercaptopentylthio) - 1,2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (6-Mercaptohexylthio) -1,2, 5-thiadiazol-4-yl) -1,2, 5, 6- tetrahydro-1-methylpyridine; 3- (3- (4-Mercaptobutylthio) - 1,2, 5-thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (4-Cyanobenzylthio) -1, 2 , 5-thiadiazol-4-yl) -1,2,5,6- tetrahydro-1-methylpyridine; 3- (3- (4-Bromobenzylthio) -1,2,5- thiadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (4-Methylbenzylthio) -1,2, 5-thiadiazol-4-yl) -1,2,5,6- tetrahydro-1-methy-l-pyridine; 3- (3-Benzylthio-l, 2 , 5- - thiadiazol-4-yl) -1, 2 , 5, 6-tetrahydro-l-methylpyridine; 3- (3- (4-Cyanobenzylthio) -1,2, 5-thiadiazol-4-yl) -1,2,5,6- tetrahydro-1, 6-dimethylpyridine; 3- (3-Hexyloxy-l , 2 , 5- oxadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- Butyloxy-1, 2 , 5-oxadiazol-4-yl) -1,2,5, 6-tetrahydro-1- methylpyridine; 3- (3- (3-Hexynyloxy) -1, 2 , 5-oxadiazol-4-yl) - 1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3- (3- Phenylpropylthio) -1,2, 5-oxadiazol-4-yl) -1,2,5, 6-tetrahydro- l-methylpyridine; 3- (3- (2-Phenoxyethylthio) -1, 2 , 5-oxadiazol- 4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3-Pentylthio- 1,2, 5-oxadiazol-4-yl) -1,2,5, 6-tetrahydro-l-methylpyridine; 3- (3-Hexylthio-l, 2, 5-oxadiazol-4-yl) -1,2,5, 6-tetrahydro-l- methylpyridine; and 3- (3- (4-Pentynylthio) -1, 2 , 5-oxadiazol-4- yl) -1,2,5, 6-tetrahydro-l-methylpyridine .
A more particularly preferred compound of formula II is xanomeline, 3- (4-hexyloxy-l, 2 , 5-thiadiazol-3-yl) -1, 2 , 5, 6- tetrahydro-1-methylpyridine .
Preferred compounds of formula III are 2- [exo- (+/-) -3- [1-azabicyclo [3.2.1] octyloxy) ]pyrazine, 3-butylthio-2- (1- azabicyclo [2.2.2] ocytl-3-oxy) ] pyrazine, 3-butyloxy-2- [3-+- endo- (1-azabicyclo [2.2.1] heptyloxy) ] pyrazine, 3-(2- butynyloxy) -2- [6-±-endo- (1- azabicyclo [3.2.1] octyloxy) pyrazine, 3-hexylthio-2- [6-±-exo- (2 -azabicyclo [2.2.1] heptyloxy) ] yrazine, 3- (3- phenylpropynylthio) -2- [2-±-exo- (7-azabicyclo [2.2.1] heptyloxy) ]pyrazine, 3- (2-methylthioethoxy) -2- [3-±-exo- (1- azabicyclo [3.2.1] octyloxy) ] pyrazine, 3-propargyl-2- [4- (1- azabicyclo [2.2.1] heptyloxy) ] pyrazine, and 3- cyclopropylmethylthio-2- [2-+-exo- (8-azabicyclo [3.2.1] octyloxy) ] pyrazine
When the present invention is regarded in its broadest sense, the first component is either a typical or an atypical antipsychotic. Similarly, when the invention is regarded in its broadest sense, the second component compound is a compound which functions as a muscarinic agonist . It will be understood that while the use of a single typical antipsychotic or a single atypical antipsychotic as a first component compound is preferred, combinations of two or more antipsychotic may be used as a first component if necessary or desired. Similarly, while the use of a single muscarinic agonist as a second component compound is preferred, combinations of two or more muscarinic agonists may be used as a second component if necessary or desired.
While all combinations of first and second component compounds are useful and valuable, certain combinations are particularly valued and are preferred. In general, combinations and methods of treatment using an atypical antipsychotic as the first component are preferred. Particularly preferred combinations and methods of treatment using olanzapine as the first component are preferred. Furthermore, combinations and methods of treatment using xanomeline as the second component are preferred. Especially preferred are combinations and methods use olanzapine as the first component and xanomeline as the second component. It is especially preferred that when the first component is olanzapine, it will be the Form II olanzapine polymorph as described in U.S. Patent No. 5,229,382. Form II olanzapine is characterized by x-ray powder diffraction pattern, of a well prepared sample, having an interplanar spacing at 10.2689. The x-ray diffraction pattern of Form II olanzapine can be obtained using a Siemens D5000 x-ray powder diffractometer having a copper Kα radiation source of wavelength, λ=l-541A. It is further preferred that the Form II olanzapine polymorph will be administered as the substantially pure Form II olanzapine polymorph. As used herein "substantially pure" refers to Form II associated with less than about 5% Form I, preferably less than about 2% Form I, and more preferably less than about 1% Form I. Further,
"substantially pure" Form II will contain less than about 0.5% related substances, wherein "related substances" refers to undesired chemical impurities or residual solvent or water. In particular, "substantially pure" Form II should contain less than about 0.05% content of acetonitrile, more preferably, less than about 0.005% content of acetonitrile. Additionally, the polymorph of the invention should contain less than 0.5% of associated water.'
Though Form II olanzapine is preferred it will be understood that as used herein, the term "olanzapine" embraces all solvate and polymorphic forms except where specifically indicated.
As used in this application the following terms have the meanings indicated: The term "halogen" means a fluoro, chloro, bromo, or iodo atom.
The term "Cx-xs-alkyl" represents a branched or linear alkyl group having from one to fifteen carbon atoms. Typical Cι-ι5 alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, butyl, iso-butyl, sec- butyl, tert-butyl, pentyl, hexyl , heptyl, octyl, nonyl, decyl, and the like.
• The term "Cι-4-alkyl" represents a branched or linear alkyl group having from one to four carbon atoms . Typical C1-C4 alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, butyl, iso-butyl, sec-butyl, and tert-butyl. The term " Cι-6-alkyl" represents a branched or linear alkyl group having from one to six carbon atoms. Typical Cι-ιs alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, butyl, iso- butyl, sec-butyl, tert-butyl, pentyl, hexyl , and the like.
The term "C2-15-alkenyl" represents an branched or linear group having from two to fifteen carbon atoms and at least one double bond. Examples of such groups include, but are not limited to, 1-propenyl, 2-propenyl, 1-butenyl, hexenyl, pentenyl, hexenyl, heptenyl, octenyl, and the like.
The term "C2-5-alkenyl" represents an branched or linear group having from two to five carbon atoms and at least one double bond. Examples of such groups include, but are not limited to, 1-propenyl, 2-propenyl, 1- butenyl , pentenyl, 2 , 2-dimethylpropenyl , and the like. The term "C2-C15 alkynyl" • refers to an unsaturated branched or linear group having from two to fifteen carbon atoms and at least one triple bond. Examples of such groups include, but are not limited to, 1-propynyl, 2-propynyl, 1- butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 1-hexynyl, 1- heptynyl, and the like.
The term "C2-5-alkynyl" refers to an unsaturated branched or linear group having from two to five carbon atoms and at least one triple bond. Examples of such groups include, but are not limited to, 1-propynyl, 2- propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, and the like.
The term "C3-C10 cycloalkyl" represents cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, and cyclodecyl .
The term "C4-12- (cycloalkylalkyl) " refers to a C3-C10 cycloalkyl linked to a "Cι-4-alkyl group in such a manner that the total number of carbon atoms in the group is between 4 and 12. Typical C - 2- (cycloalkylalkyl) groups include cyclopropylmethyl, eye1opropylethyl , cyclopropylpropyl, cyclopropylbutyl, cyclobutylmethyl , cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylmethyl, 3-cyclopentylpropyl, and the like.
The term "Cχ-4-alkoxy" represents a branched or linear alkyl group having from one to four carbon atoms attached through and oxygen atom. Typical Cι-4-alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, iso-propoxy, butoxy, and the like.
The term "pharmaceutically acceptable salts" include the physiologically acceptable salts which are often used in pharmaceutical chemistry. Many such salts are described in Journal of Pharmaceutical Science, 66 , 2 (1977) . It will be understood by the skilled reader that some of the compounds used in the present invention are capable of forming salts, and that the salt forms of pharmaceuticals are commonly used, often because they are more readily crystallized and purified than are the free bases. In all cases, the use of the pharmaceuticals described above as salts is contemplated in the description herein, and often is preferred, and the pharmaceutically acceptable salts of all of the compounds are included in the names of them. It is- also understood that the term "pharmaceutically acceptable salts" refers to acid addition and base addition salts. Thus, a pharmaceutically acceptable salt is formed from a pharmaceutically acceptable acid or a pharmaceutically- acceptable base as is well known in the art. Typical inorganic acids used to form acid addition salts include hydrochloric, hydrobromic, hydriodic, nitric, sulfuric, phosphoric, hypophosphoric, metaphosphoric, pyrophosphoric, and the like. Acid addition salts derived from organic acids, such as aliphatic mono and dicarboxylic acids, phenyl substituted alkanoic acids, hydroxyalkanoic and hydroxyalkandioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, may also be used. Such pharmaceutically acceptable salts thus include acetate, phenylacetate, trifluoroacetate, acrylate, ascorbate, benzoate, chlorobenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, methylbenzoate , o-acetoxybenzoate, naphthalene-2-benzoate, isobutyrate, phenylbutyrate, hydroxybutyrate, butyne-1, 4-dicarboxylate, hexyne-1,4- dicarboxylate, caprate, caprylate, cinnamate, citrate, formate, fumarate, glycollate, heptanoate, hippurate, lactate, malate, maleate, hydroxymaleate, malonate, mandelate, mesylate, nicotinate, isonicotinate, nitrate, oxalate, phthalate, teraphthalate, propiolate, propionate, phenylpropionate, salicylate, sebacate, succinate, suberate, benzene-sulfonate, p-bromobenzenesulfonate, chlorobenzenesulfonate, ethanesulfonate, 2- hydroxyethanesulfonate, methanesulfonate, naphthalene-1- sulfonate, naphthalene-2-sulfonate, p-toluenesulfonate, xylenesulfonate, tartarate, and the like. Typical base addition salts include lithium, sodium, potassium, calcium, magnesium, aluminum, and the like.
The following examples are included to more specifically describe the preparation of the compounds used in the method of this invention. These examples are not intended to limit the present invention in any way. The terms used in the following examples and preparations have their normal meanings unless otherwise designated. For example "°C" refers to degrees Celsius; ; "mmol" refers to millimole or millimoles; "kg" refers to kilogram or kilograms; "g" refers to gram or grams; "mg" refers to milligram or milligrams; "mL" refers milliliter or milliliters; "L" refers to liter or liters; "brine" refers to a saturated aqueous sodium chloride solution; "min" refers to minute; "h" refers to hours, etc.
EXAMPLE 1
Synthesis of xanomeline
To a solution of sulfurmonochloride (2.4 ml, 30 mmol) in N,N-dimethylformamide (5 ml) was slowly added alpha- aminoalpha (3 -pyridyl) acetonitrile (Archive der Pharmazie 289 (4) (1956)) (1.70 g, 10 mmol) . The reaction mixture was stirred at room temperature for 18 h. Water (20 ml) was added and the aqueous phase was extracted with ether and the ,^
H
CM
,#
+
S
•^
. u co
^
H
• ft s
Dl
Figure imgf000025_0001
ε
Figure imgf000025_0002
EXAMPLE 2
Technical grade olanzapine
Figure imgf000026_0001
Intermediate 1
In a suitable three neck flask the following was added:
Dimethylsulfoxide (analytical) : 6 volumes
Intermediate 1 : 75 g N-Methylpiperazine (reagent) : 6 equivalents
Intermediate 1 can be prepared using methods known to the skilled artisan. For example, the preparation of the Intermediate 1 is taught in US Patent No. 5,229,382.
A sub-surface nitrogen sparge line was added to remove the ammonia formed during the reaction. The reaction was heated to 120°C and maintained at that temperature throughout the duration of the reaction. The reactions were followed by HPLC until 5% of the intermediate 1 was left unreacted. After the reaction was complete, the mixture was allowed to cool slowly to 20°C (about 2 hours) . The reaction mixture was then transferred to an appropriate three neck round bottom flask and water bath. To this solution with agitation was added 10 volumes reagent grade methanol and the reaction was stirred at 20°C for 30 minutes. Three volumes of water was added slowly over about 30 minutes. The reaction slurry was cooled to zero to 5°C and stirred for 30 minutes. The product was filtered and the wet cake was washed with chilled methanol . The wet cake was dried in vacuo at 45°C overnight. The product was identified as technical olanzapine. Yield: 76.7%; Potency: 98.1%
EXAMPLE 3
Form II olanzapine polymorph
A 270 g sample of technical grade 2 -methyl-4- (4-methyl- 1-piperazinyl) -lOH-thieno [2 , 3-b] [1, 5] benzodiazepine was suspended in anhydrous ethyl acetate (2.7 L) . The mixture was heated to 76oC and maintained at 76oC for 30 minutes. The mixture was allowed to cool to 25oC. The resulting product was isolated using vacuum filtration. The product was identified as Form II using x-ray powder analysis. Yield: 197 g.
The process described above for preparing Form II provides a pharmaceutically elegant product having potency > 97%, total related substances < 0.5% and an isolated yield of > 73%.
According to the present invention the combination is usually administered in the form of pharmaceutical compositions. The adjunctive therapy of the present invention is carried out by administering a first component together with the second component in any manner which provides effective levels of the compounds in the body at the same time. Oral administration of the adjunctive combination is preferred. They may be administered together, in a single dosage form, or may be administered separately.
Oral administration is not the only route or even the only preferred route. For example, transdermal administration may be very desirable for patients who are forgetful or petulant about taking oral medicine. One of the drugs may be administered by one route, such as oral, and the others may be administered by the transdermal, percutaneous, intravenous, intramuscular, intranasal or intrarectal route, in particular circumstances. The route of administration may be varied in any way, limited by the physical properties of the drugs and the convenience of the patient and the caregiver. The adjunctive combination may be administered as a single pharmaceutical composition, and so pharmaceutical compositions incorporating both compounds are important embodiments of the present invention. Such compositions may take any physical form which is pharmaceutically acceptable, but orally usable pharmaceutical compositions are particularly preferred. Such adjunctive pharmaceutical compositions contain an effective amount of each of the compounds, which effective amount is related to the daily dose of the compounds to be administered. Each adjunctive dosage unit may contain the daily doses of all compounds, or may contain a fraction of the daily doses, such as one-third or one-half of the doses. Alternatively, each dosage unit may contain the entire dose of one of the compounds, and a fraction of the dose of the other compounds. In such case, the patient would daily take one of the combination dosage units, and one or more units containing only the other compounds. The amounts of each drug to be contained in each dosage unit depends on the identity of the drugs chosen for the therapy, and other factors such as the indication for which the adjunctive therapy is being given.
The inert ingredients and manner of formulation of the adjunctive pharmaceutical compositions are conventional, except for the presence of the combination of the present invention. The usual methods of formulation used in pharmaceutical science may be used here. All of the usual types of compositions may be used, including tablets, chewable tablets, capsules, solutions, parenteral solutions, intranasal sprays or powders, troches, suppositories, transdermal patches and suspensions. In general, compositions contain from about 0.5% to about 50% of the compounds in total, depending on the desired doses and the type of composition to be used. The amount of the compounds, however, is best defined as the effective amount, that is, the amount of each compound which provides the desired dose to the patient in need of such treatment . The activity of the adjunctive combinations do not depend on the nature of the composition, so the compositions are chosen and formulated solely for convenience and economy. Any of the combinations may be formulated in any desired form of composition. Some discussion of different compositions will be provided, followed by some typical formulations. Capsules are prepared by mixing the compound with a suitable diluent and filling the proper amount of the mixture in capsules. The usual diluents include inert powdered substances such as starch of many different kinds, powdered cellulose, especially crystalline and microcrystalline cellulose, sugars such as fructose, mannitol and sucrose, grain flours and similar edible powders .
Tablets are prepared by direct compression, by wet granulation, or by dry granulation. Their formulations usually incorporate diluents, binders, lubricants and disintegrators as well as the compound. Typical diluents include, for example, various types of starch, lactose, mannitol, kaolin, calcium phosphate or sulfate, inorganic salts such as sodium chloride and powdered sugar. Powdered cellulose derivatives are also useful. Typical tablet binders are substances such as starch, gelatin and sugars such as lactose, fructose, glucose and the like. Natural and synthetic gums are also convenient, including acacia, alginates, methylcellulose, polyvinylpyrrolidone and the like. Polyethylene glycol, ethylcellulose and waxes can also serve as binders.
A lubricant is necessary in a tablet formulation to prevent the tablet and punches from sticking in the die . The lubricant is chosen from such slippery solids as talc, magnesium and calcium stearate, stearic acid and hydrogenated vegetable oils. SQ
90 ■ f 4-1
^ CQ
O -H
CΛ 4-1 β
H Φ J -H α. J
CQ rH re υ
- l
4J β
Φ
CJ rti ε iH
(ti
XI ft φ xl
4-1
4H
0 β
0
-rl
4J rti ε
0
4H β
■H
TJ β rβ
Tf 4J
90 CQ φ
© SH ϊ Φ o 4J
O β
-rl
Figure imgf000030_0001
Formulation 1 Hard gelatin capsules are prepared using the following ingredients :
Quantity
(mg/capsule)
Olanzapine 25 mg
Xanomeline 80
Starch, dried 150
Magnesium stearate 10
Total 265 mg
Formulation 2
A tablet is prepared using the ingredients below: Quantity (mg/tablet)
Olanzapine 10
Fluoxetine, racemic, hydrochloride 80 Cellulose, microcrystalline 275
Silicon dioxide, fumed 10 Stearic acid 5_
Total 375 mg
The components are blended and compressed to form tablets.
Conditioned Avoidance Behavior in Rats: In a conditioned avoidance test, animals learn to respond during a conditioned stimulus in order to avoid mild shock presentation. A response during the conditioned stimulus is termed an avoidance response, a response during shock is termed an escape response; a response failure is when the animal fails to respond during either the conditioned stimulus or the shock presentation and is indicative of motor impairment. Animals rapidly learn to avoid 99% of the time. Antipsychotic drugs decrease the percentage of avoidance responses without interfering with the ability of the animal to respond since the animals do emit escape responses . The percentage of response failures is considered a measure of motor impairment. Procedure :
Rats were required to press a response lever in an experimental chamber in order to avoid or escape foot-shock. Each experimental session consisted of 50 trials. During each trial, the chamber was illuminated and a tone presented for a maximum of 10 sec. A response during the tone immediately terminated the tone and the houselight, ending the trial . In the absence of a response during the tone alone, tone+foot-shock (2.0 mA) was presented for a maximum of 10 sec. A response during shock presentation immediately terminated the shock, the tone and the houselight, ending the trial.
The synergistic effects of the present combinations can be demonstrated by administering an inactive or relatively inactive dose of one component (such as the selected muscarinic agonist) and various doses of the other component. If the effects are simply additive the results will be additive. If the effects of are synergistic, then the dose of second component required to produce full efficacy will be decreased. In particular, if the dose of both components are inactive when administered alone, but produce full efficacy when given in combination, then the combination is synergistic.
Results for representative combinations of the present invention are given in the table below.
Figure imgf000033_0001
Figure imgf000034_0001

Claims

We claim:
1. A method for treating a patient suffering from or susceptible to psychosis, comprising administering to the patient an effective amount a first component which is a typical antipsychotic or an atypical antipsychotic and an effective amount of a second component which is a muscarinic agonist .
2. A method of Claim 1 where the first component is olanzapine and the second component is xanomeline.
3. A method of Claim 1 wherein the patient is suffering from schizophrenia.
4. A method of Claim 2 wherein the patient is suffering from schizophrenia.
5. A method of treating a patient suffering or susceptible to Alzheimer's disease, comprising administering to the patient an effective amount a first component which is a typical antipsychotic or an atypical antipsychotic and an effective amount of a second component which is a muscarinic agonist.
6. A pharmaceutical composition comprising an effective amount a first component which is a typical antipsychotic or an atypical antipsychotic and a second component which is a muscarinic agonist.
7. The use of a first component which is a typical antipsychotic or an atypical antipsychotic and an effective amount of a second component which is a muscarinic agonist for the manufacture of a medicament for treating psychosis.
8. A use of Claim 7 where the first component is olanzapine and the second component is xanomeline.
9. A use of Claim 7 wherein the patient is suffering from schizophrenia.
10. A use of Claim 8 wherein the patient is suffering from schizophrenia.
11. The use of a first component which is a typical antipsychotic or an atypical antipsychotic and an effective amount of a second component which is a muscarinic agonist for the manufacture of a medicament for treating Alzheimer's disease .
PCT/US2001/014863 2000-06-30 2001-06-18 Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist WO2002003684A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2002507636A JP2004502655A (en) 2000-06-30 2001-06-18 Combination therapy for treatment of mental illness
US10/296,738 US20040023951A1 (en) 2001-06-18 2001-06-18 Combination therapy for treatment of psychoses
AU2001268055A AU2001268055A1 (en) 2000-06-30 2001-06-18 Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist
EP01945949A EP1316203A2 (en) 2000-06-30 2001-06-18 Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist
CA002411386A CA2411386A1 (en) 2000-06-30 2001-06-18 Combination therapy for treatment of psychoses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21551600P 2000-06-30 2000-06-30
US60/215,516 2000-06-30

Publications (2)

Publication Number Publication Date
WO2002003684A2 true WO2002003684A2 (en) 2002-01-10
WO2002003684A3 WO2002003684A3 (en) 2003-03-13

Family

ID=22803282

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/014863 WO2002003684A2 (en) 2000-06-30 2001-06-18 Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist

Country Status (5)

Country Link
EP (1) EP1316203A2 (en)
JP (1) JP2004502655A (en)
AU (1) AU2001268055A1 (en)
CA (1) CA2411386A1 (en)
WO (1) WO2002003684A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006067496A1 (en) * 2004-12-23 2006-06-29 Minster Research Limited Combination of sabcomeline with a neuroleptic agent to treat psychotic disorders
WO2006067494A1 (en) * 2004-12-23 2006-06-29 Minster Research Limited Sabcomeline alone or combined with a mood stabilising or antimanic agent to treat bipolar disorders
US7678363B2 (en) * 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
US9315458B2 (en) 2014-04-23 2016-04-19 Takeda Pharmaceutical Company, Limited Nitrogen-containing heterocyclic compound
US9878989B2 (en) 2015-06-26 2018-01-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10548899B2 (en) 2015-10-20 2020-02-04 Takeda Pharmaceutical Company Limited Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity
EP4091607A1 (en) * 2021-05-18 2022-11-23 Karuna Therapeutics, Inc. Methods for treating central nervous system disorders with muscarinic receptor activator xanomeline and antipsychotics

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2804215C (en) 2009-07-22 2019-10-01 Eric Elenko Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
AU2019346626B2 (en) 2018-09-28 2022-06-02 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarinic receptor activation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0830864A1 (en) * 1996-09-23 1998-03-25 Eli Lilly And Company Combination therapy for treatment of psychoses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0830864A1 (en) * 1996-09-23 1998-03-25 Eli Lilly And Company Combination therapy for treatment of psychoses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HARLAN E. SHANNON ET ALL.: "Xanomeline, an M1/M4 preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats ans mice." SCHIZOPHRENIA RESEARCH, vol. 42, 5 May 2000 (2000-05-05), pages 249-259, XP002219641 *
SAUERBERG P ET AL: "Identification of side chains on 1,2,5-thiadiazole-azacycles optimal for muscarinic m1 receptor activation" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 8, no. 20, 20 October 1998 (1998-10-20), pages 2897-2902, XP004139582 ISSN: 0960-894X *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006067496A1 (en) * 2004-12-23 2006-06-29 Minster Research Limited Combination of sabcomeline with a neuroleptic agent to treat psychotic disorders
WO2006067494A1 (en) * 2004-12-23 2006-06-29 Minster Research Limited Sabcomeline alone or combined with a mood stabilising or antimanic agent to treat bipolar disorders
US7678363B2 (en) * 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
US10624875B2 (en) 2012-11-14 2020-04-21 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9868725B2 (en) 2014-04-23 2018-01-16 Takeda Pharmaceutical Company Limited Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimer's disease
US9518042B2 (en) 2014-04-23 2016-12-13 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
US9675597B2 (en) 2014-04-23 2017-06-13 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
US9775827B2 (en) 2014-04-23 2017-10-03 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
US9789083B2 (en) 2014-04-23 2017-10-17 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
US9789084B2 (en) 2014-04-23 2017-10-17 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
US9655881B2 (en) 2014-04-23 2017-05-23 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
US10865200B2 (en) 2014-04-23 2020-12-15 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
US9315458B2 (en) 2014-04-23 2016-04-19 Takeda Pharmaceutical Company, Limited Nitrogen-containing heterocyclic compound
US9662316B2 (en) 2014-04-23 2017-05-30 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
US9499516B2 (en) 2014-04-23 2016-11-22 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
US10457670B2 (en) 2014-04-23 2019-10-29 Takeda Pharmaceutical Company Limited Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimers disease
US10428056B2 (en) 2015-06-26 2019-10-01 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10323027B2 (en) 2015-06-26 2019-06-18 Takeda Pharmaceutical Company Limited 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor
US10087150B2 (en) 2015-06-26 2018-10-02 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9878989B2 (en) 2015-06-26 2018-01-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10899752B2 (en) 2015-06-26 2021-01-26 Takeda Pharmaceutical Company Limited 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor
US10548899B2 (en) 2015-10-20 2020-02-04 Takeda Pharmaceutical Company Limited Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity
EP4091607A1 (en) * 2021-05-18 2022-11-23 Karuna Therapeutics, Inc. Methods for treating central nervous system disorders with muscarinic receptor activator xanomeline and antipsychotics

Also Published As

Publication number Publication date
CA2411386A1 (en) 2002-01-10
WO2002003684A3 (en) 2003-03-13
JP2004502655A (en) 2004-01-29
EP1316203A2 (en) 2003-06-04
AU2001268055A1 (en) 2002-01-14

Similar Documents

Publication Publication Date Title
US5945416A (en) Method for treating pain
US5739151A (en) Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
CZ288984B6 (en) Pharmaceutical preparation for inhibiting Alzheimer&#39;s disease, for increasing TGF- beta expression in the brain, for inhibition of inflammatory response associated with Alzheimer&#39;s disease and for inhibiting beta-amyloid peptide mediated neurotoxicity
EP1838310A1 (en) Combination of sabcomeline with a neuroleptic agent to treat psychotic disorders
US20040023951A1 (en) Combination therapy for treatment of psychoses
JP5684388B2 (en) Methods for treating antipsychotic-induced weight gain
EP1316203A2 (en) Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist
US20090258084A1 (en) Mono and Combination Therapy with a M1/M4 Muscarinic Agonist (Sabcomeline) for Treatment of Cognitive Disorders in Schizophrenia
CA2167004C (en) Agent for treating mental disorders associated with cerebrovascular disorders
US20090306040A1 (en) Mono and Combination Therapy of M1/M4 Agonist (Sabcomeline) for Treatment of Negative Symptoms of Schizophrenia
US6147093A (en) Methods for treating gastroesophageal reflux disease
WO2007125287A1 (en) Mono and combination therapy with m1/m4 muscarinic agonist (sabcomeline) for treatment of prodromal syndrome
AU721290B2 (en) Method for treating migraine pain
AU780107B2 (en) Methods for treating emesis and central nervous system disorders using optically pure () norcisapride

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10296738

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2411386

Country of ref document: CA

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2002 507636

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001945949

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001945949

Country of ref document: EP